🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma

Recruitingn/aAges 18 Years - 75 YearsAllRuijin Hospital
NCT07795528 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This multicenter prospective observational cohort study will enroll 392 patients with stage I-III colon adenocarcinoma who undergo curative resection and whose tumors harbor at least one prespecified oncogenic driver mutation (KRAS, NRAS, BRAF, or PIK3CA). Serial plasma circulating tumor DNA (ctDNA) testing for molecular residual disease (MRD) will be performed with a standardized 10-gene next-generation sequencing (NGS) panel at predefined time points during 3 years of postoperative follow-up. The primary objective is to evaluate the association between postoperative ctDNA-based MRD status and recurrence-free survival (RFS). Secondary objectives include evaluating overall survival (OS), the interval between first MRD detection and radiologically confirmed recurrence, and the association between longitudinal MRD changes and outcomes following adjuvant chemotherapy.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-75 years, regardless of sex 2. Pathologically confirmed colon adenocarcinoma, clinical stage I-III without preoperative endoscopic submucosal dissection (ESD) or endoscopic mucosal resection (EMR) 3. Planned curative surgical resection, no prior anti-tumor therapy (chemotherapy, radiotherapy, targeted therapy) before surgery 4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 5. Tumor tissue positive for at least one driver mutation among KRAS, NRAS, BRAF, PIK3CA 6. Voluntary participation with signed written informed consent, good compliance with scheduled follow-up and blood collection. Exclusion Criteria: 1. Received neoadjuvant chemotherapy, radiotherapy or targeted therapy before surgery 2. History of other malignant tumors (excluding non-adenomatous colorectal neoplasms) 3. Pregnant or breastfeeding women 4. Severe concurrent systemic diseases that interfere with long-term follow-up or short-term survival (uncontrolled severe infection, organ failure, mental disorders, or other serious conditions) 5. Abnormal laboratory values or social/family factors judged by investigator to impede sample collection and follow-up 6. Simultaneous participation in other interventional clinical trials with mandatory assigned postoperative treatment regimen
💊

What it tests

  • Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points
📍

Where

1 site
Ruijin Hospital North
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy